Trial intelligence / Profile preview

Real-world study of pyrotinib maleate for brain metastases from HER2-positive solid tumors

ChiCTR2200058265Phase 4Not yet recruiting

Sponsor
Beijing Tiantan Hospital
Start
Mar 2022
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of pyrotinib in Nonhematologic neoplasms and brain metastases, sponsored by Beijing Tiantan Hospital. Primary endpoint: Progression-Free Survival. Planned start Mar 2022; status: not yet recruiting.

02

Drugs

pyrotinib
03

Conditions

Nonhematologic neoplasmsbrain metastases

Beyond the preview

Go deeper on ChiCTR2200058265.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2200058265.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call